2012, Número 4
<< Anterior Siguiente >>
Ann Hepatol 2012; 11 (4)
Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement
Teschke R, Frenzel C, Wolff A, Herzog J, Glass X, Schulze J, Eickhoff A
Idioma: Ingles.
Referencias bibliográficas: 45
Paginas: 500-512
Archivo PDF: 133.55 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Aronson JK. Adverse drug reactions: History, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson JK. Stephens’ detection and evaluation of adverse drug reactions: principles and practice. 6th. Ed. John Wiley & Sons, Ltd.; 2011. DOI: 10.1002/ 9780470975053. ch1.
Lynn E, Layton D, Shakir S. New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UK. Drug Saf 2011; 34: 89-91.
Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, et al; International Society for Pharmacoepidemiology; International Society for Pharmacovigilance. Guidelines for submitting adverse events reports for publication. Drug Saf 2007; 30: 367-73.
Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions. Drug Saf 2010; 30: 765-73.
Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-70.
Hung SK, Hillier S, Ernst E. Case reports of adverse effects of herbal medicinal products (HMPs): A quality assessment. Phytomedicine 2011; 18: 335-43.
Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann Hepatol 2009; 8: 184-95.
García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ; on behalf of the Spanish Group for the Study of Drug-Induced Liver Disease. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol 2011; 55: 683-91.
Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity- Causality assessment versus safety signal. Quality versus quantity. Maturitas 2009; 64: 141-42.
EMA (European Medicines Agency). Assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2011/06/WC500107717.pdf [Issued March 31, 2011; accessed February 20, 2012].
Drug Commission of the German Medical Association (Arzneimittelkommission der Deutschen Ärzteschaft). Hepatitis in connection with Umckaloabo®. Deutsches Ärzteblatt 2011; 108: C1399-C1400 (article in German).
Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012; 63: 1-9.
Danan G, Bénichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.
Teschke R, Schmidt-Taenzer W, Wolff A. USP suspected herbal hepatotoxicity: Quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmacoepidemiol Drug Saf 2012; 21: 336-338.
Teschke R, Schulze J. Suspected herbal hepatotoxicity: Requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012 [In press].
Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: A systematic review of adverse events. Drug Saf 2005; 28: 319-32.
Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am J Obstet Gynecol 2008; 199: 455-66.
Chan TYK. Potential risks associated with the use of herbal anti-obesity products. Drug Saf 2009; 32: 453-6.
Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (Saw Palmetto): A systematic review of adverse events. Drug Saf 2009; 3: 637-47.
Saokaew S, Suwankesawong W, Permsuwan U, Chaiyakunapruk N. Safety of herbal products in Thailand: An analysis of reports in the Thai Health Product Vigilance Center Database from 2000 to 2008. Drug Saf 2011; 34: 339-50.
Seeff KB. Herbal hepatotoxicity. Clin Liv Dis 2007; 11: 577-96.
Shaw D. Pilot case control study of Chinese herbs and liver toxicity. Drug Saf 2008; 31: 885-960.
Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 29: 373-82.
Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol 2009; 5: 843-60.
Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: Is the liver unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf 2011; 20: 567-82.
Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011; 11: 249-59.
Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-93.
Teschke R. Kava hepatotoxicity-a clinical review. Ann Hepatol 2010; 9: 251-65.
Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011; 61: 282-91.
Teschke R, Glass X, Schulze J, Eickhoff A. Suspected Greater Celandine hepatotoxicity: Liver specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol 2012; 24: 270-80.
Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 1999; 319: 1541.
Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731-5.
Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanches de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-30.
Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, et al; Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
Dalton HR, Fellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow U, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007; 26: 1429-35.
Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, et al; for the Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141: 1665-72.
Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifuga racemosa rhizoma (black cohosh, root): Critical analysis and structured causality assessment. Phytomedicine 2009; 16: 72-84.
Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009; 16: 956-65.
Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff W. Suspected black cohosh hepatotoxicity- Challenges and pitfalls of causality assessment. Maturitas 2009; 63: 302-14.
Teschke R. Black cohosh and suspected hepatotoxicity-inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: A critical review. Menopause 2010; 17: 426-40.
Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? Regul Toxicol Pharmacol 2011; 59: 1-7.
WHO. Causality assessment of suspected adverse reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database. Available at: www.who-umc.org/DynPage.aspx?id=22682 [Accessed February 20, 2012].
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.